TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06500364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoopLoc Arm
Description: Patients in this intervention will have had a capsular closure performed using a LoopLoc device after their hip arthroscopy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm
Description: Patients in this intervention will have not had a capsular closure using a LoopLoc device after their hip arthroscopy.
Study: NCT05021640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-AUD
Description: DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and uptake after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DCR-AUD
Description: DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and uptake after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-AUD
Description: DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and uptake after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DCR-AUD
Description: DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and uptake after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for DCR-AUD
Description: 0.9% saline for injection
Study: NCT06015204

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block targeting the C5-to-C6 nerve roots
Description: With the head rotated contralateral to interscalene brachial plexus block (ISBPB), the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery under ultrasound guidance. The linear ultrasound transducer is moved cephalad until the C5-to-C8 nerve roots are visualized between the anterior and middle scalene muscles. A block needle is introduced from lateral to medial direction. A nerve root is blocked by placing at least 5 ml of 0.75% ropivacaine around it. The most caudal cervical nerve root (C6 nerve root) is blocked first, and the most cephalad one (C5 nerve root) is blocked last. Then, 3 ml of 0.75% ropivacaine is placed between the scalene and sternocleidomastoid muscles to block the supraclavicular nerves. An equivalent volume of a standard study drug is planned to be used (A total of 25 ml of 0.75% ropivacaine).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block targeting the C5-to-C8 nerve roots
Description: With the head rotated contralateral to interscalene brachial plexus block (ISBPB), the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery under ultrasound guidance. The linear ultrasound transducer is moved cephalad until the C5-to-C8 nerve roots are visualized between the anterior and middle scalene muscles. A block needle is introduced from lateral to medial direction. A nerve root is blocked by placing at least 5 ml of 0.75% ropivacaine around it. The most caudal cervical nerve root (C8 nerve root) is blocked first, and the most cephalad one (C5 nerve root) is blocked last. Then, 3 ml of 0.75% ropivacaine is placed between the scalene and sternocleidomastoid muscles to block the supraclavicular nerves. An equivalent volume of a standard study drug is planned to be used (A total of 25 ml of 0.75% ropivacaine).
Study: NCT05981274

Intervention type: DIAGNOSTIC_TEST
Intervention: serum biomarker.
Description: serum biomarker:CTX-II, COMP, hsCRP, TNF-a, CTX-I, sRANKL, OPG, and Osteopontin (OPN)
Study: NCT06304259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Submucosal infiltration injection of 1 mL cryo-treated saline maintained at a temperature of 2 to 5°C before the normal local anaesthetic routine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Submucosal infiltration injection of 1 mL cryo-treated saline maintained at a temperature of 2 to 5°C before the normal local anaesthetic routine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: root canal treatment with final flush of cold saline maintained at a temperature of 2 to 5°C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: root canal treatment with final flush of cold saline maintained at a temperature of 2 to 5°C
Study: NCT05835206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microbiome Therapeutic
Description: Participants will receive a single course of study treatment (IP, Encapsulated Microbiota): Orally delivered, non-frozen, encapsulated investigational intestinal microbiota, consisting of 16 capsules. One dose (8 capsules) is administered daily (QD) for 2 days. The capsules are to be taken orally with water on an empty stomach. Each dose will be taken approximately every 24 hours, with a minimum of 12 hours from the previous dose to a maximum of 36 hours. Both doses must be completed within the stated 36 hours ±12 hours. Depending on the time of the first dose, dosing may occur over 3 calendar days.~A second cycle will begin and a second treatment will be given if the participant is still MDRO positive on Day 14 of Cycle 1. If applicable, Cycle 2 will begin within 7 days of Day 14.
Study: NCT06406569

Intervention type: DEVICE
Group type: OTHER
Intervention: H-Man Robot
Description: The HMAN is certified as a CE class 2A upper limb rehabilitation robot suitable for hospital, clinic and home-based use in 2020 by Health Sciences Authority, Singapore. It has since been employed in post-stroke neurorehabilitation therapy and assessment of sensorimotor functions in stroke patients.

Intervention type: DEVICE
Group type: OTHER
Intervention: ReHandyBot
Description: ReHandyBot is the portable version of ReHapticKnob a robot developed at ETH Zurich that provides neurocognitive therapy, focusing on hand opening and closing movements as well as prono-supination of the forearm.

Intervention type: DEVICE
Group type: OTHER
Intervention: MyoPanda
Description: MyoPanda is a passive wrist/hand device which patients use to train the hand and wrist function by controlling a virtual avatar with EMG activity measures.
Study: NCT05835206

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single course of study treatment (Color-matched placebo capsules containing microcrystalline cellulose (MCC) powder), consisting of 16 capsules. One dose (8 capsules) is administered daily (QD) for 2 days. The capsules are to be taken orally with water on an empty stomach. Each dose will be taken approximately every 24 hours, with a minimum of 12 hours from the previous dose to a maximum of 36 hours. Both doses must be completed within the stated 36 hours ±12 hours. Depending on the time of the first dose, dosing may occur over 3 calendar days.~A second cycle will begin and a second treatment will be given if the participant is still MDRO positive on Day 14 of Cycle 1. If applicable, Cycle 2 will begin within 7 days of Day 14.
Study: NCT04817553

Intervention type: OTHER
Intervention: exposure to COVID19
Description: Observational study of IgG4 patients with pancreatobiliary involvement who were diagnosed with COVID19
Study: NCT05268133

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aronia
Description: As described in experimental arm

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: As described in placebo comparator arm
Study: NCT06231173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Feedback Therapy and Conventional Therapy
Description: In experimental group individuals will receive visual feedback therapy and Conventional rehabilitation therapy. In visual feedback therapy, bilateral method is used to receive the visual feedback from the mirror. This visual feedback therapy consists of the following parts as the patient is asked to follow the involved hand that did the mimicking while the non-involved side will be performing wrist flexion, wrist extension, ulnar deviation, radial deviation, supination, pronation, and closing hand and opening hand.In conventional therapy, Patients are given a rest time of 20 seconds in each activity and a 1-minute break in each segment in order to reduce fatigue of the noninvolved hand. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied according to subject's tolerance for duration of 15 minutes in each sitting. This treatment protocol will be 5 times/week for 4 weeks in the hospital setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: In control group individuals will receive only conventional therapy. In conventional therapy, Patients are instructed to perform a sandbag and hand grip exercise with a resistive exercise for the non-involved side. At last, patients are instructed to perform a moving small object (ball of wool) and card flip operation to induce wrist and finger movements as functional activities. Patients are given a rest time of 20 seconds in each activity and a 1-minute break in each segment in order to reduce fatigue of the non involved hand. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied according to subject's tolerance for duration of 15 minutes in each sitting. .This treatment protocol will be 5 times/week for 4 weeks in the hospital setting.
Study: NCT06129773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: antibiotic coated vicryl used for fascial closure
Description: in this group fascial closure was done with antibiotic coated vicryl to compare with non coated vicryl after lapaprotomy in contaminated wounds
Study: NCT05493787

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminder
Description: Patient portal, SMS, email, and/or another modality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Patient portal, SMS, email, and/or another modality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Patient portal, SMS, email, and/or another modality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Patient portal, SMS, email, and/or another modality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Patient portal, SMS, email, and/or another modality
Study: NCT06635681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined chemotherapy
Description: Induction therapy(1 cycle):~Daunorubicin 60mg/m2/d d1-3 Cytarabine 100mg/m2/d d1-7 Venetoclax 100mg d-2, 200mg d-1, 400mg d1-7 If the first course of treatment did not result in CR, patients with therapeutic target could be treated with targeted drugs, and the patients without targets would be treated with HAV regimen: Cytarabine 100mg/m2/d, d1-5, Homoharringtonine 2mg/m2 d1-5, Venetoclax 100mg d-2, 200mg d-1, 400mg d1-7.~Consolidation therapy(3 cycles):~Cytarabine 2g/m2 q12h d1-3 Venetoclax 400mg d1-7 For patients with CBF and CEBPA dual mutations, the dose of cytarabine is 3g/m2.~Maintenance treatment(6 cycles):~Azacitidine 75mg/m2/d d1-5 Venetoclax 400mg d1-7~Allogeneic hematopoietic stem cell transplantation is recommended for high-risk groups and intermediate-risk with positive measurable residual disease.
Study: NCT04260230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lifetemp/Lifetouch sensors
Description: Wearing the devices for six weeks. Data only reviewed retrospectively.
Study: NCT05601492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Otezla - Standard Care
Description: The participant will be given their medication with the electronic adapter cap on it and asked to return for the follow-up visit
Study: NCT06556433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive Rewards
Description: Participants in the Rewards Group will have abstinence reinforced through escalating financial incentives.
Study: NCT05361577

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exoplulse Mollii suit
Description: Exopulse Mollii suits consists of a body Garments (Jacket and Pants) and a control unit. The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate 40 groups of muscles, conductive wires and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body. The control unit is a battery powered electrical device which sends low intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Exopulse Mollii suit (sham)
Description: In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
Study: NCT05617157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stair stepping
Description: stepping up and down 32 stairs for 1 minute
Study: NCT05601492

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminder Text Intervention with apremilast
Description: Participants will receive a weekly electronic text/email-based intervention that is designed to promote better adherence to treatment in addition to receiving their medication with the electronic adapter cap on it.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder Text Intervention with apremilast
Description: Participants will receive a weekly electronic text/email-based intervention that is designed to promote better adherence to treatment in addition to receiving their medication with the electronic adapter cap on it.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extended Consultation for apremilast
Description: Participants will be given their medication with the electronic adapter cap on it and will receive an initial patient consult intervention, which will focus on medication education and setting expectations of what to anticipate with usage of the prescribed medication

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Consultation for apremilast
Description: Participants will be given their medication with the electronic adapter cap on it and will receive an initial patient consult intervention, which will focus on medication education and setting expectations of what to anticipate with usage of the prescribed medication
Study: NCT04906993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab； famitinib malate
Description: Camrelizumab intravenously ; Famitinib Orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platinum-based chemotherapy
Description: Physician's choice chemotherapy
Study: NCT06286137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to music for 1 minute
Description: Participants will be instructed to make a 20-minute playlist with their own preferred music, using a tablet and a music listening app. That playlist will then be presented on shuffle mode for 1 minute through headphones provided by the hospital. Volume can be selected by the participants. However, in order to prevent hearing loss the volume cannot exceed 80 decibels. The 19 minutes before the 1 minute music listening intervention, participants will be instructed to remain seated and are not allowed to do anything else (for example using their phones).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to music for 5 minutes
Description: Participants will be instructed to make a 20-minute playlist with their own preferred music, using a tablet and a music listening app. That playlist will then be presented on shuffle mode for 1 minute through headphones provided by the hospital. Volume can be selected by the participants. However, in order to prevent hearing loss the volume cannot exceed 80 decibels. The 15 minutes before the 5 minutes music listening intervention, participants will be instructed to remain seated and are not allowed to do anything else (for example using their phones).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to music for 20 minutes
Description: Participants will be instructed to make a 20-minute playlist with their own preferred music, using a tablet and a music listening app. That playlist will then be presented on shuffle mode for 20 minutes through headphones provided by the hospital. Volume can be selected by the participants. However, in order to prevent hearing loss the volume cannot exceed 80 decibels.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Not listening to music
Description: Participants will be instructed to remain seated and are not allowed to do anything else (for example using their phones), for a duration of 20 minutes.
Study: NCT05145569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin AUC 5 and paclitaxel
Description: Carboplatin AUC 5 and paclitaxel combination chemotherapy is very well tolerated and highly effective for the treatment of ovarian cancer and thus is standard of care therapy. Both carboplatin and paclitaxel are chemotherapy agents that are designed to kill and slow the growth of cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5 and paclitaxel
Description: Carboplatin AUC 5 and paclitaxel combination chemotherapy is very well tolerated and highly effective for the treatment of ovarian cancer and thus is standard of care therapy. Both carboplatin and paclitaxel are chemotherapy agents that are designed to kill and slow the growth of cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCW9218
Description: HCW9218 is an immunotherapeutic comprising transforming growth factor-b (TGF-b) receptor II and interleukin (IL)-15/IL-15 receptor a domains.
Study: NCT05656664

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic acid supplementation to assess for increased arsenic metabolite excretion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group to assess arsenic metabolite excretion
Study: NCT04535401

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo imaging
Study: NCT05508048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The existential approach and logotherapy-based psychosocial support program
Description: Existential Approach and Logotherapy Based Support Program, which raises awareness about the meaning and purpose of the individual's life, enables them to produce solutions to the sense of meaninglessness, anxiety, feeling of emptiness, and many other problems, and develops different perspectives.The content of the program is base on existential analysis and logotherapy. The program lasted for eight weeks, with the first and last session of the scale applications. Additional sessions were set for each session where the aims and objectives of the session could not achieve. A session lasting at least 50 minutes were held each week.
Study: NCT05817149

Intervention type: PROCEDURE
Intervention: Blood samples
Description: Blood samples
Study: NCT04535401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study: NCT05801029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib will be administered as 80 mg oral tablet once daily (from Day 2) until progression of disease or until a study intervention discontinuation criterion is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as an IV infusion at 1050 mg (\< 80 kg body weight) or 1400mg (≥ 80 kg body weight) (in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1 to 2) and then every 2 weeks in subsequent cycles) until progression of disease or until a study intervention discontinuation criterion is met. The first cycle dose is spilt over 2 days- 350 mg on day 1 and 700 mg \[body weight \< 80 kg\] or 1050 mg \[body weight ≥ 80 kg\] on day 2.
Study: NCT05924789

Intervention type: OTHER
Intervention: Observational study
Description: This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.

Intervention type: OTHER
Intervention: Observational study
Description: This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
Study: NCT05569252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1211b
Description: DS-1211b tablet administered once daily in the morning either in the fasted state or with a meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1211b
Description: DS-1211b tablet administered once daily in the morning either in the fasted state or with a meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1211b
Description: DS-1211b tablet administered once daily in the morning either in the fasted state or with a meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet administered once daily in the morning either in the fasted state or with a meal